Assigned Interventions CD19/BCMA CAR T-cells

BIOLOGICAL4 trials

Sponsors

Zhejiang University

Conditions

Autoimmune DiseasesImmune NephritisLupus NephritisSclerodermaSjogren's SyndromeSystemic Lupus Erythematosus

Early Phase 1

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

Zhejiang UniversityAutoimmune Diseases, Systemic Lupus Erythematosus

Start: 2021-09-10End: 2022-09-10Target: 9Updated: 2021-09-01

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

Zhejiang UniversityAutoimmune Diseases, Immune Nephritis, Lupus Nephritis

Start: 2021-11-05End: 2024-11-05Target: 9Updated: 2021-10-20

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

Zhejiang UniversityAutoimmune Diseases, Sjogren's Syndrome

Start: 2021-11-05End: 2024-11-05Target: 9Updated: 2021-10-20

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

Zhejiang UniversityAutoimmune Diseases, Scleroderma

Start: 2021-10-08End: 2024-10-08Target: 9Updated: 2021-10-20

Related Papers

Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.

2025-09-244 citations

Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial

Blood2022-11-1516 citations